Information Provided By:
Fly News Breaks for June 10, 2019
ILMN
Jun 10, 2019 | 07:58 EDT
Canaccord analyst Mark Massaro raised his price target on Illumina to $360 from $350 following meeting with management. The analyst said he sees a multi-year path to growth ahead in research and clinical sequencing. He acknowledged there are near-term risks but said he is confident that demand for high-margin sequencing consumables is intact and that the company's commitment to R&D spending coupled with its best in class people, will enable it to maintain its leadership position for years. Massaro reiterated his Buy rating on Illumina shares.
News For ILMN From the Last 2 Days
There are no results for your query ILMN